Healthcare Company Announces Positive Clinical Trial Results For GAD
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder.
In a significant development for the field of mental health, biopharmaceutical company Incannex Healthcare Limited (ASX: IHL) has announced positive topline results from its Phase 2 Psi-GAD1 clinical trial of psilocybin in Generalised Anxiety Disorder (GAD). $Incannex Healthcare(IXHL.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
